To amend section 1751.01 and to enact sections 3902.65 and 5164.11 of the Revised Code concerning insurance and Medicaid coverage for specified infertility services.
HB 888 would require Ohio health benefit plans and Medicaid to cover specified infertility services. The bill amends the definition of basic health care services in the insurance code and adds new sections requiring coverage for assisted reproductive technology and for treatment of conditions that impact fertility. It defines assisted reproductive technology to include procedures such as in vitro fertilization, gamete intrafallopian transfer, and zygote intrafallopian transfer, while excluding treatments like intrauterine insemination and medication-only ovulation stimulation when eggs are not retrieved.
The bill also requires coverage for a broad set of fertility-related medical treatments aimed at addressing underlying conditions that affect conception, such as endometriosis, polycystic ovary syndrome, uterine fibroids, primary ovarian insufficiency, sperm disorders, infections, structural reproductive problems, and ovulation disorders. For private health benefit plans, the required fertility coverage must be provided to the same extent as other medical procedures and treatments for female reproductive care or male infertility treatments, and any cost-sharing for these services cannot exceed the plan’s cost-sharing for comparable services. The Medicaid program would be subject to a similar mandate.
In addition to the new fertility coverage mandates, the bill revises Ohio’s health insuring corporation statute to expressly include certain infertility services among basic health care services that may be covered. It leaves existing insurance law structure in place but expands the list of services that plans may be required to cover when they offer basic health care services. The practical effect would be to broaden mandated benefits for insurers and to create a parallel coverage requirement for Medicaid.
The bill’s overall sentiment appears supportive of expanded reproductive health access, with no recorded committee testimony or votes in the provided materials indicating opposition or amendment activity. Because the bill was only introduced and referred to the House Insurance Committee, there is no formal voting history to show broader legislative support or resistance. The framing of the bill suggests a policy goal of reducing financial barriers to infertility diagnosis and treatment.
The main point of potential contention is cost and scope. Insurers and Medicaid administrators could view the mandate as increasing premiums, claims costs, and program expenditures, especially because the bill requires coverage of assisted reproductive technology and related treatments on parity with other reproductive care. Another possible issue is the bill’s specific definition of covered services, including what is and is not included in assisted reproductive technology, which could affect implementation and coverage disputes.
HB 888 would amend Ohio insurance law by adding infertility-related services to mandated coverage for health benefit plans and by expressly including infertility services in the definition of basic health care services for health insuring corporations. It would also create a new Medicaid coverage requirement, section 5164.11, directing the state Medicaid program to cover assisted reproductive technology and treatment for conditions that impact fertility on the same terms as comparable reproductive health services. The bill would therefore affect private insurers, Medicaid managed care and fee-for-service coverage decisions, and enrollees seeking fertility diagnosis and treatment.
The available context shows a generally favorable posture toward expanding infertility coverage, with the bill introduced by bipartisan cosponsors and no recorded committee debate, testimony, or votes in the materials provided. Because the measure has only been introduced and referred to committee, there is no evidence here of formal opposition or support beyond the bill’s sponsorship. The bill’s purpose and structure indicate a pro-access, pro-coverage sentiment focused on reproductive health and family-building services.
The likely areas of contention are the fiscal and administrative effects of mandating coverage for assisted reproductive technology and related fertility treatments. Insurers may object to higher claims costs and premium impacts, while Medicaid officials may be concerned about increased program spending. Another possible point of dispute is the bill’s scope and definitions, including which fertility treatments are included, how parity with other reproductive care is measured, and whether the mandate could lead to coverage disputes over procedures such as IVF, insemination, or medication-based treatment.